Journal article
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
Miguel Martin, Henri Roche, Tomas Pinter, John Crown, M John Kennedy, Louise Provencher, Frank Priou, Wolfgang Eiermann, Encarna Adrover, Istvan Lang, Manuel Ramos, Jean Latreille, Agnieszka Jagiello-Gruszfeld, Tadeusz Pienkowski, Emilio Alba, Raymond Snyder, Sachin Almel, Janusz Rolski, Montserrat Munoz, Rebecca Moroose Show all
LANCET ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2011
Abstract
BACKGROUND: Vascular endothelial growth factor (VEGF) has a crucial role in angiogenesis, and is a valid target in metastatic breast cancer. Motesanib is an investigational oral inhibitor of VEGF receptors. We aimed to determine whether treatment with motesanib plus paclitaxel is better than placebo plus paclitaxel in patients with HER2-negative locally recurrent or metastatic breast cancer. METHODS: Between Dec 1, 2006, and July 4, 2008, patients with untreated HER2-negative metastatic breast cancer were randomly assigned (using a randomisation list created by personnel not associated with the study) in a 1:1:1 ratio to paclitaxel (90 mg/m(2) on days 1, 8, and 15 every 3 weeks) plus either ..
View full abstractGrants
Funding Acknowledgements
MM has received speaker's honoraria from Amgen, and has served as a consultant for that company. TP has received consultancy and speaker's honoraria from Amgen. Roche, and Novartis. JC has received speaker's honoraria from Amgen. LP was an advisory board member and consultant for Amgen, has received payment for lectures/speaker's bureaus from Roche, Amgen, and Abraxis, and has received travel support from Roche and Novartis. JL has received payment for lectures or speakers bureaus from Roche. AB, HA, and Y-JH are employees of Amgen and owns Amgen stock. M-AL, MR, DC, and YL are employees of CIRG, which was contracted by Amgen for this study. JRM has received speaker's honoraria from Amgen and Roche. SH was an advisory board member and consultant for Lilly, Abraxis, and BM S, and has received payment for lectures/speaker's bureaus from Lilly, Abraxis, and Physicians Education Resource, has received travel support from CRIG, and has received royalties from MCGraw Hill. All other authors declared no conflicts of interest.